B
Bicara Therapeutics Inc. (BCAX)
NGM – Real Time Price. Currency in USD
22.38
-0.54 (-2.36%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
22.38
-0.54 (-2.36%)
At close: May 12, 2026, 4:00 PM EDT
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | CEO & Director |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs |
| Mr. Ivan Hyep M.B.A. | CFO & Treasurer |
| Mr. Jean-Paul Rodrique | Senior VP & Global Head of Quality Assurance |
| Mr. Ryan Cohlhepp Pharm.D. | President, COO & Director |
| Ms. Angela Windt | VP & Head of Regulatory Affairs |
| Ms. Lara S. Meisner J.D. | Chief Legal Officer, Compliance Officer & Corporate Secretary |
| Ms. Pauline Dufresne | Chief People Officer |
| Ms. Rachel Salazar | SVP of R&D Strategy and Operations |
| Ms. Sathish Hasige Ph.D. | Senior VP and Head of Technical Operations & Supply Chain |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 8-K | bcax-20260511.htm |
| 2026-04-27 | DEFA14A | defa14anotice2026.htm |
| 2026-04-27 | DEF 14A | bcax-20260427.htm |
| 2026-03-31 | S-8 | bicara-sx8evergreeninducem.htm |
| 2026-03-30 | 8-K | bcax-20260330.htm |
| 2026-03-30 | 10-K | bcax-20251231.htm |
| 2026-02-26 | 8-K | d938194d8k.htm |
| 2026-02-19 | 8-K | bcax-20260219.htm |
| 2026-01-12 | 8-K | bcax-20260112.htm |
| 2025-12-08 | 8-K | bcax-20251206.htm |